Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The report serves as a notification regarding a directorate change rather than a financial results announcement.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance updates.
Material Changes
The filing confirms the appointment of Sir Philip Hampton as a Non-Executive Director, effective January 1, 2015. The Company states there are no further disclosures required under Listing Rule 9.6.13R regarding this appointment.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items.
Key Facts for Investors
- Sir Philip Hampton is appointed as a Non-Executive Director effective January 1, 2015.
- This filing confirms no additional disclosures are required regarding the directorate change.
- No financial performance data is included in this specific report.